Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma.

about

Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q55001263

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma.

@en

Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma.

@nl

type

Item

label

Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma.

@en

Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma.

@nl

prefLabel

Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma.

@en

Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma.

@nl

P1476

Prognostic and therapeutic value of CD103+ cells in renal cell carcinoma.

@en

P2093

Bingxin Lu

http://www.w3.org/2001/XMLSchema#string

Jin Zhou

http://www.w3.org/2001/XMLSchema#string

Lipeng Liu

http://www.w3.org/2001/XMLSchema#string

Tuo Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Microenvironmental regulation of tumor progression and metastasis

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Oncology meets immunology: the cancer-immunity cycle.

Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity

Intratumoral dendritic cells in the anti-tumor immune response

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.

TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease.

P304

4979-4986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/ETM.2018.6025

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29805521

http://www.w3.org/2001/XMLSchema#string

P932

5952092

http://www.w3.org/2001/XMLSchema#string